ReviewAntiviral chemistry & chemotherapy
Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus.
Review in Antiviral chemistry & chemotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge.Human vaccines & immunotherapeutics · 2026Article
- Catching our breath: development of interventions and therapies for respiratory syncytial virus.Microbiology and molecular biology reviews : MMBR · 2026Review
- Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins.Cell host & microbe · 2026Article
- Pathological Characteristics of the Lung and Brain in Cotton Rats and BALB/c Mice Infected with Respiratory Syncytial Virus.Viruses · 2026Article
- Potency Evaluation and Predictive Quality Control System Construction Strategy for Respiratory Syncytial Virus mRNA Vaccines.Vaccines · 2026Review
- Development of a potent monoclonal antibody for treatment of human metapneumovirus infections.Nature communications · 2026Article
- Article
- Metavac-RSV mucosal bivalent vaccine candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor.NPJ vaccines · 2025Article
- Prostaglandin D2 delays CD8+ T-cell responses and respiratory syncytial virus clearance in geriatric cotton rats.Journal of virology · 2025Article
- Self-amplifying mRNA vaccines protect elderly BALB/c mice against a lethal respiratory syncytial virus infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Cotton Rat Model of Respiratory Syncytial Virus Infection.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Lethal model for respiratory syncytial virus infection using C57BL/6 mice.Journal of virology · 2024Article
- Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Animal models of mpox virus infection and disease.Infectious medicine · 2023Review
- Cross-protective antibodies against common endemic respiratory viruses.Nature communications · 2023Article
- Alzheimer's disease and multiple sclerosis: a possible connection through the viral demyelinating neurodegenerative trigger (vDENT).Frontiers in aging neuroscience · 2023Article
- Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions.Frontiers in pharmacology · 2023Review
- ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves.Nature communications · 2022Article
- Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque.Journal of virology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus is the leading cause of pneumonia and bronchiolitis in infants and is a serious health risk for elderly and immunocompromised individuals. No vaccine has yet been approved to prevent respiratory syncytial virus infection and the only available treatment is immunoprophylaxis of severe respiratory syncytial virus disease in high-risk infants with Palivizumab (Synagis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.